Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Nov 1;11(11):CD006683.
doi: 10.1002/14651858.CD006683.pub3.

Prophylactic non-steroidal anti-inflammatory drugs for the prevention of macular oedema after cataract surgery

Blanche X Lim  1 , Chris Hl Lim, Dawn K Lim, Jennifer R Evans, Catey Bunce, Richard Wormald
Affiliations
Meta-Analysis

Prophylactic non-steroidal anti-inflammatory drugs for the prevention of macular oedema after cataract surgery

Blanche X Lim et al. Cochrane Database Syst Rev. .

Abstract

Background: Macular oedema (MO) is the accumulation of extracellular fluid in the central retina (the macula). It may occur after cataract surgery and may give rise to poor visual outcome, with reduced visual acuity and distortion of the central vision. MO is often self-limiting with spontaneous resolution, but a small proportion of people with chronic persistent MO may be difficult to treat. Chronic oedema may lead to the formation of cystic spaces in the retina termed 'cystoid macular oedema' (CMO). Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used in cataract surgery and may reduce the chances of developing MO.

Objectives: The aim of this review is to answer the question: is there evidence to support the prophylactic use of topical NSAIDs either in addition to, or instead of, topical steroids postoperatively to reduce the incidence of macular oedema (MO) and associated visual morbidity.

Search methods: We searched a number of electronic databases including CENTRAL, MEDLINE and Embase. Date last searched 2 September 2016.

Selection criteria: We included randomised controlled trials (RCTs) in which adult participants had undergone surgery for age-related cataract. We included participants irrespective of their baseline risk of MO, in particular we included people with diabetes and uveitis. We included trials of preoperative and/or postoperative topical NSAIDs in conjunction with postoperative topical steroids. The comparator was postoperative topical steroids alone. A secondary comparison was preoperative and/or postoperative topical NSAIDs alone versus postoperative topical steroids alone.

Data collection and analysis: Two review authors independently selected studies for inclusion, assessed risk of bias and extracted data using standard methods expected by Cochrane. We pooled data using a random-effects model. We graded the certainty of the evidence using GRADE and considered the following: risk of bias of included studies, precision of the effect estimate, consistency of effects between studies, directness of the outcome measure and publication bias.

Main results: We identified 34 studies that were conducted in the Americas, Europe, the Eastern Mediterranean region and South-East Asia. Over 5000 people were randomised in these trials. The majority of studies enrolled one eye per participant; a small subset (4 trials) enrolled a proportion of people with bilateral surgery. Twenty-eight studies compared NSAIDs plus steroids with steroids alone. Six studies compared NSAIDs with steroids. A variety of NSAIDs were used, including ketorolac, diclofenac, nepafenac, indomethacin, bromfenac, flurbiprofen and pranopfen. Follow-up ranged from one to 12 months. In general, the studies were poorly reported. We did not judge any of the studies at low risk of bias in all domains. Six studies were funded by industry, seven studies were funded from non-industry sources, and the rest of the studies did not report the source of funding.There was low-certainty evidence that people receiving topical NSAIDs in combination with steroids may have a lower risk of poor vision due to MO at three months after cataract surgery compared with people receiving steroids alone (risk ratio (RR) 0.41, 95% confidence interval (CI) 0.23 to 0.76; eyes = 1360; studies = 5; I2 = 5%). We judged this to be low-certainty evidence because of risk of bias in the included studies and indirectness, as the extent of visual loss was not always clear. Only one study reported poor vision due to MO at 12 months and we judged this to be very low-certainty evidence as there were only two events. Quality of life was only reported in one of the 34 studies comparing NSAIDs plus steroids versus steroids alone, and it was not fully reported, other than to comment on lack of differences between groups. There was evidence of a reduced risk of MO with NSAIDs at three months after surgery, but we judged this to be low-certainty due to risk of bias and publication bias (RR 0.40, 95% CI 0.32 to 0.49; eyes = 3638; studies = 21). There was inconsistent evidence on central retinal thickness at three months (I2 = 87%). Results ranged from -30.9 µm in favour of NSAIDs plus steroids to 7.44 µm in favour of steroids alone. Similarly, data on best corrected visual acuity (BCVA) were inconsistent, but nine out of 10 trials reporting this outcome found between-group differences in visual acuity of less than 0.1 logMAR.None of the six studies comparing NSAIDs alone with steroids reported on poor vision due to MO at three or 12 months. There was low-certainty evidence that central retinal thickness was lower in the NSAIDs group at three months (mean difference (MD) -22.64 µm, 95% CI -38.86 to -6.43; eyes = 121; studies = 2). Five studies reported on MO and showed a reduced risk with NSAIDs, but we judged this evidence to be of low-certainty (RR 0.27, 95% CI 0.18 to 0.41; eyes = 520). Three studies reported BCVA at three months and the results of these trials were inconsistent, but all three studies found differences of less than 0.1 logMAR between groups.We did not note any major adverse events - the main consistent observation was burning or stinging sensation with the use of NSAIDs.

Authors' conclusions: Using topical NSAIDs may reduce the risk of developing macular oedema after cataract surgery, although it is possible that current estimates as to the size of this reduction are exaggerated. It is unclear the extent to which this reduction has an impact on the visual function and quality of life of patients. There is little evidence to suggest any important effect on vision after surgery. The value of adding topical NSAIDs to steroids, or using them as an alternative to topical steroids, with a view to reducing the risk of poor visual outcome after cataract surgery is therefore uncertain. Future trials should address the remaining clinical uncertainty of whether prophylactic topical NSAIDs are of benefit, particularly with respect to longer-term follow-up (at least to 12 months), and should be large enough to detect reduction in the risk of the outcome of most interest to patients, which is chronic macular oedema leading to visual loss.

PubMed Disclaimer

Conflict of interest statement

JE: None known BL: Noneknown CL: None known DL: None known CB: None known RW: None known.

Figures

1
1
Study flow diagram.
2
2
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
3
3
Funnel plot of comparison: 1 NSAIDs plus steroids versus steroids, outcome: 1.4 Macular oedema.
4
4
Funnel plot of comparison: 2 NSAIDs versus steroids, outcome: 2.2 Macular oedema.
1.1
1.1. Analysis
Comparison 1 NSAIDs plus steroids versus steroids, Outcome 1 Poor vision due to MO.
1.2
1.2. Analysis
Comparison 1 NSAIDs plus steroids versus steroids, Outcome 2 Central retinal thickness.
1.3
1.3. Analysis
Comparison 1 NSAIDs plus steroids versus steroids, Outcome 3 Total macular volume.
1.4
1.4. Analysis
Comparison 1 NSAIDs plus steroids versus steroids, Outcome 4 Macular oedema.
1.5
1.5. Analysis
Comparison 1 NSAIDs plus steroids versus steroids, Outcome 5 Inflammation.
1.6
1.6. Analysis
Comparison 1 NSAIDs plus steroids versus steroids, Outcome 6 Inflammation (flare).
1.7
1.7. Analysis
Comparison 1 NSAIDs plus steroids versus steroids, Outcome 7 BCVA.
2.1
2.1. Analysis
Comparison 2 NSAIDs versus steroids, Outcome 1 Central retinal thickness.
2.2
2.2. Analysis
Comparison 2 NSAIDs versus steroids, Outcome 2 Macular oedema.
2.3
2.3. Analysis
Comparison 2 NSAIDs versus steroids, Outcome 3 Inflammation (flare).
2.4
2.4. Analysis
Comparison 2 NSAIDs versus steroids, Outcome 4 BCVA.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD006683.pub2

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Almeida 2008 {published data only}
    1. Almeida DR, Johnson D, Hollands H, Smallman D, Baxter S, Eng KT, et al. Effect of prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery. Journal of Cataract and Refractive Surgery 2008;34(1):64‐9. [DOI: 10.1016/j.jcrs.2007.08.034] - DOI - PubMed
Almeida 2012 {published data only}
    1. Almeida DR, Khan Z, Xing L, Bakar SN, Rahim K, Urton T, et al. Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification. Journal of Cataract and Refractive Surgery 2012;38(9):1537‐43. [DOI: 10.1016/j.jcrs.2012.04.034] - DOI - PubMed
    1. El‐Defrawy SR, Almeida DR. Randomized controlled trial comparing nepafenac, ketorolac and placebo in preventing macular oedema after uncomplicated cataract extraction. West Indian Medical Journal 2000;61:29.
Asano 2008 {published data only}
    1. Asano S, Miyake K, Ota I, Sugita G, Kimura W, Sakka Y, et al. Reducing angiographic cystoid macular edema and blood‐aqueous barrier disruption after small‐incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0.1%. Journal of Cataract and Refractive surgery 2008;34(1):57‐63. [DOI: 10.1016/j.jcrs.2007.08.030] - DOI - PubMed
Brown 1996 {published data only}
    1. Brown RM, Roberts CW. Preoperative and postoperative use of nonsteroidal antiinflammatory drugs in cataract surgery. Insight (American Society of Ophthalmic Registered Nurses) 1996;21(1):13‐6. - PubMed
Cervantes‐Coste 2009 {published data only}
    1. Cervantes‐Coste G, Sánchez‐Castro YG, Orozco‐Carroll M, Mendoza‐Schuster E, Velasco‐Barona C. Inhibition of surgically induced miosis and prevention of postoperative macular edema with nepafenac. Clinical Ophthalmology 2009;3(1):219‐26. - PMC - PubMed
Chatziralli 2011 {published data only}
    1. Chatziralli IP, Papazisis L, Sergentanis TN. Ketorolac plus tobramycin/dexamethasone versus tobramycin/dexamethasone after uneventful phacoemulsification surgery: a randomized controlled trial. Ophthalmologica 2011;225(2):89‐94. [DOI: 10.1159/000317067] - DOI - PubMed
Donnenfeld 2006 {published data only}
    1. Donnenfeld ED, Perry HD, Wittpenn JR, Solomon R, Nattis A, Chou T. Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic‐response curve. Journal of Cataract and Refractive Surgery 2006;32(9):1474‐82. [DOI: 10.1016/j.jcrs.2006.04.009] - DOI - PubMed
Elsawy 2013 {published data only}
    1. Elsawy MF, Badawi N, Khairy HA. Prophylactic postoperative ketorolac improves outcomes in diabetic patients assigned for cataract surgery. Clinical Ophthalmology 2013;7:1245‐9. [DOI: ] - PMC - PubMed
Endo 2010 {published data only}
    1. Endo N, Kato S, Haruyama K, Shoji M, Kitano S. Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. Acta Ophthalmologica 2010;88(8):896‐900. [DOI: 10.1111/j.1755-3768.2009.01582.x] - DOI - PubMed
    1. Kitano S, Endo N, Shoji M, Haruyama K, Kato S. Effect of bromfenac sodium ophthalmic solution on preventing cystoids macular edema and inflammation after phacoemulsification and implantation of intraocular lens in diabetic patients. Investigative Ophthalmology and Visual Science 2008;49(3):ARVO E‐abstract 3470.
Italian Diclofenac Study Group 1997 {published data only}
    1. Italian Diclofenac Study Group. Efficacy of diclofenac eyedrops in preventing postoperative inflammation and long‐term cystoid macular edema. Italian Diclofenac Study Group. Journal of Cataract and Refractive Surgery 1997;23(8):1183‐9. - PubMed
Jung 2015 {published data only}
    1. Jung JW, Chung BH, Kim EK, Seo KY, Kim TI. The effects of two non‐steroidal anti‐inflammatory drugs, bromfenac 0.1% and ketorolac 0.45%, on cataract surgery. Yonsei Medical Journal 2015;56:1671‐7. - PMC - PubMed
Kraff 1982 {published data only}
    1. Kraff MC, Sanders DR, Jampol LM, Peyman GA, Lieberman HL. Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. Ophthalmology 1982;89(8):885‐90. - PubMed
Li 2011 {published data only}
    1. Li M‐C, Yang X‐R, Liu F, Shao D‐P, Li Y‐B. Effect of topical NSAIDs in preventing macular edema after phacoemulsification in diabetes. International Journal of Ophthalmology 2011;11(9):1614‐6. [DOI: 10.3969/j.issn.1672-5123.2011.09.039] - DOI
Mathys 2010 {published data only}
    1. Mathys KC, Cohen KL. Impact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedema. Eye 2010;24(1):90‐6. [DOI: 10.1038/eye.2009.10] - DOI - PubMed
Miyake 2007 {published data only}
    1. Miyake K, Nishimura K, Harino S, Ota I, Asano S, Kondo N, et al. The effect of topical diclofenac on choroidal blood flow in early postoperative pseudophakias with regard to cystoid macular edema formation. Investigative Ophthalmology & Visual Science 2007;48(12):5647‐52. [DOI: 10.1167/iovs.07-0262] - DOI - PubMed
Miyake 2011 {published data only}
    1. Miyake K, Ota I, Miyake G, Numaga J. Nepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery 2011;37(9):1581‐8. [DOI: 10.1016/j.jcrs.2011.03.052] - DOI - PubMed
Miyanaga 2009 {published data only}
    1. Miyanaga M, Miyai T, Nejima R, Maruyama Y, Miyata K, Kato S. Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery. Acta Ophthalmologica 2009;87(3):300‐5. [DOI: 10.1111/j.1755-3768.2008.01433.x] - DOI - PubMed
Moschos 2012 {published data only}
    1. Moschos MM, Chatziralli IP, Pantazis P, Rouvas AA, Sergentanis TN. Is topical diclofenac essential before and after uneventful phacoemulsification cataract surgery?. Journal of Ocular Pharmacology and Therapeutics 2012;28(4):335‐9. [DOI: 10.1089/jop.2011.0256] - DOI - PubMed
Quentin 1989 {published data only}
    1. Quentin CD, Behrens‐Baumann W, Gaus W. Prevention of cystoid macular edema with diclofenac eyedrops in intracapsular cataract extraction using the Choyce Mark IX anterior chamber lens. Fortschritte der Ophthalmologie 1989;86(6):546‐9. - PubMed
Rossetti 1996 {published data only}
    1. Rossetti L, Bujtar E, Castoldi D, Torrazza C, Orzalesi N. Effectiveness of diclofenac eyedrops in reducing inflammation and the incidence of cystoid macular edema after cataract surgery. Journal of Cataract and Refractive Surgery 1996;22 Suppl 1:794‐9. - PubMed
    1. Torrazza C, Rossetti L, Castoldi D, Bujtar E, Orzalesi N. Effectiveness of diclofenac eyedrops in reducing postoperative inflammation angiographic cme after cataract surgery. Investigative Ophthalmology & Visual Science 1995;36:ARVO E‐Abstract 3769.
Singh 2012 {published data only}
    1. Pollack A, Narvekar A, Adewale A, Singh R. A post‐hoc analysis comparing nepafenac (0.1%) to vehicle treatment post‐cataract surgery in patients with diabetic retinopathy. Ophthalmologica 2014;232:20‐1.
    1. Pollack A, Sager D, Singh R. Risk reduction of macular edema with nepafenac (0.1%) post‐cataract surgery in patients with diabetic retinopathy: Efficacy and safety from 2 multicenter trials. Ophthalmologica 2014;232:20.
    1. Singh R, Alpern L, Jaffe GJ, Lehmann RP, Lim J, Reiser HJ, et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clinical Ophthalmology 2012;6(1):1259‐69. [DOI: 10.2147/OPTH.S31902] - DOI - PMC - PubMed
Solomon 1995 {published data only}
    1. Solomon LD. Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema. Flurbiprofen‐CME Study Group I. Journal of Cataract and Refractive Surgery 1995;21(1):73‐81. - PubMed
    1. Solomon LD, Boyaner D, Breslin CW, Demco TA, Fabian E, LeBlanc RP, et al. Topical flurbiprofen and indomethacin inhibit postoperative cystoid macular edema (CME). American Academy of Ophthalmology 1990:120.
Tauber 2006 {published data only}
    1. Tauber S, Gessler J, Scott W, Peterson C, Hamlet P. The effect of topical ketorolac 0.4% on cystoid macular edema following routine cataract surgery. Investigative Ophthalmology & Visual Science 2006;47:ARVO E‐abstract 683.
Ticly 2014 {published data only}
    1. Ticly FG, Lira RP, Zanetti FR, Machado MC, Rodrigues GB, Arieta CE. Prophylactic use of ketorolac tromethamine in cataract surgery: a randomized trial. Journal of Ocular Pharmacology and Therapeutics 2014;30(6):495‐501. [DOI: ] - PubMed
Tunc 1999 {published data only}
    1. Tunc M, Saatci OA, Ergin MH, Ergin S. Cystoid macular edema early after uncomplicated cataract surgery: The efficacy of diclofenac in prophylaxis. Annals of Ophthalmology ‐ Glaucoma 1999;31(1):27‐32.
Tzelikis 2015 {published data only}
    1. Tzelikis PF, Vieira M, Hida WT, Motta AF, Nakano CT, Nakano EM, et al. Comparison of ketorolac 0.4% and nepafenac 0.1%for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo‐controlled randomised study. British Journal of Ophthalmology 2015;99:654‐8. - PubMed
Umer‐Bloch 1983 {published data only}
    1. Umer‐Bloch U. Prevention of cystoid macular edema following cataract extraction using local indomethacin application. Klinische Monatsblätter für Augenheilkunde 1983;183(6):479‐84. [DOI: 10.1055/s-2008-1054988] - DOI - PubMed
    1. Umer‐Bloch U. Should indomethacin be used topically to prevent aphakic cystoid macular edema? [Indocid Lokal Zur Pravention Des Postoperativen Zystoiden Makulaodems?]. Klinische Monatsblätter für Augenheilkunde 1983;182(5):495‐6.
Wang 2013 {published data only}
    1. Wang QW, Yao K, Xu W, Chen PQ, Shentu XC, Xie X, et al. Bromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for control of ocular inflammation and prevention of cystoid macular edema after phacoemulsification. Ophthalmologica 2013;229(4):187‐94. [DOI: 10.1159/000346847] - DOI - PubMed
Wittpenn 2008 {published data only}
    1. Rocha G. A randomized, masked comparison of topical ketorolac 0.4% plus steroid versus steroid alone in low‐risk cataract surgery patients. Evidence‐Based Ophthalmology 2009;10(2):92‐3. - PubMed
    1. Wittpenn J, Silverstein SM, Hunkeler JD, Schechter B, Price FW, Chu YR, et al. A masked comparison of acular LS plus steroid vs. steroid alone for the prevention of macular leakage in cataract patients. American Academy of Ophthalmology 2006:197.
    1. Wittpenn JR, Silverstein S, Heier J, Kenyon KR, Hunkeler JD, Earl M, et al. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low‐risk cataract surgery patients. American Journal of Ophthalmology 2008;146(4):554‐60. [DOI: ] - PubMed
Yannuzzi 1981 {published data only}
    1. Yannuzzi LA, Landau AN, Turtz AI. Incidence of aphakic cystoid macular edema with the use of topical indomethacin. Ophthalmology 1981;88(9):947‐54. - PubMed
Yavas 2007 {published data only}
    1. Yavas GF, Oztürk F, Küsbeci T. Preoperative topical indomethacin to prevent pseudophakic cystoid macular edema. Journal of Cataract and Refractive Surgery 2007;33(5):804‐7. [DOI: 10.1016/j.jcrs.2007.01.033] - DOI - PubMed
Yung 2007 {published data only}
    1. Yung CW, Hui SL, Wang J, Gao H, Peracha MO, Pratt LM, et al. The effect of topical ketorolac tromethamine 0.5% on macular thickness in diabetic patients after cataract surgery. American Academy of Ophthalmology 2007:208.
Zaczek 2014 {published data only}
    1. Zaczek A, Artzen D, Laurell CG, Stenevi U, Montan P. Nepafenac 0.1% plus dexamethasone 0.1% versus dexamethasone alone: effect on macular swelling after cataract surgery. Journal of Cataract and Refractive Surgery 2014;40(9):1498‐505. [DOI: ] - PubMed
Zhang 2008 {published data only}
    1. Zhang H‐Y, Zhu S‐Q. Clinical study of Pranoprofen eyedrops on prophylaxis of cystoids macular edema after cataract surgery. International Journal of Ophthalmology 2008;8(7):1370‐2.

References to studies excluded from this review

Abelson 1989 {published data only}
    1. Abelson MB, Smith LM, Ormerod LD. Prospective, randomized trial of oral piroxicam in the prophylaxis of postoperative cystoid macular edema. Journal of Ocular Pharmacology 1989;5(2):147‐53. - PubMed
Carenini 1993 {published data only}
    1. Carenini BB, Brancato R, Molfetta V, Frezzotti R, Balestrazzi E, Cardia L, et al. Indomethacin ophthalmic suspension in the prevention of cystoid macular oedema in cataract extraction patients [L'indometacina, sospensione oftalmica, nella prevenzione dell'edema maculare cistoide in pazienti sottoposti ad estrazione di cataratta]. Annali di Ottalmologia e Clinica Oculistica 1993;119(9):681‐7.
Chen 2015 {published data only}
    1. Chen J, Wang G‐Q. Clinical observation of bromfenac sodium 0.1% eye drops on cataract surgery. International Eye Science 2015;15(12):2102‐4.
Dehgan 1992 {published data only}
    1. Dehgan JA, Ustuner A, Aras C, Ozdamar A. Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. Turk Oftalmoloji Gazetesi 1992;22(2):168‐73.
Duong 2015 {published data only}
    1. Duong HV, Westfield KC, Singleton IC. Treatment paradigm after uncomplicated cataract surgery: a prospective evaluation. Acta Ophthalmologica 2015;93(4):e314‐5. [DOI: 10.1111/aos.12221] - DOI - PubMed
Hendrikse 1982 {published data only}
    1. Hendrikse F, Yamaaki H, Deutman AF. Local administration of indomethacin to prevent postoperative cystoid macular edema. Nederlands Tijdschrift voor Geneeskunde 1982;126(3):134.
Hollwich 1983 {published data only}
    1. Hollwich F, Jacobi K, Küchle HJ, Lerche W, Reim M, Straub W. Prevention of cystoid macular edema using indomethacin eye drops. Klinische Monatsblätter für Augenheilkunde 1983;183(6):477‐8. [DOI: 10.1055/s-2008-1054987] - DOI - PubMed
ISRCTN02628492 {published data only}
    1. ISRCTN02628492. Prevention of post‐cataract surgery macula oedema with prophylactic ketorolac. isrctn.com/ISRCTN02628492 (first received 6 July 2008).
Miyake 2000 {published data only}
    1. Miyake K, Masuda K, Shirato S, Oshika T, Eguchi K, Hoshi H, et al. Comparison of diclofenac and fluorometholone in preventing cystoid macular edema after small incision cataract surgery: a multicentered prospective trial. Japanese Journal of Ophthalmology 2000;44:58‐67. - PubMed
Nishino 2009 {published data only}
    1. Nishino M, Eguchi H, Iwata A, Shiota H, Tanaka M, Tanaka T. Are topical steroids essential after an uneventful cataract surgery?. Journal of Medical Investigation 2009;56(1‐2):11‐5. - PubMed
Riley 2006 {published data only}
    1. Riley AF, Wakely LA, Patel HY, Neveldsen B, Purdie GL, Wells AP. Use of a cyclo‐oxygenase 2 inhibitor for prophylaxis of cystoid macular oedema following cataract surgery: a randomized placebo‐controlled trial. Clinical and Experimental Ophthalmology 2006;34(4):299‐304. [DOI: 10.1111/j.1442-9071.2006.01213.x] - DOI - PubMed
Sanders 1982 {published data only}
    1. Sanders DR, Kraff MC, Peyman GA. Effects of indomethacin on postoperative inflammation after intraocular lens surgery. Afro‐Asian Journal of Ophthalmology 1982;1(4):149‐52.
Sellares 1992 {published data only}
    1. Sellares MT, Maseras M, Roque A, Duch F. Effect of topical indomethacin in prevention of aphakic cystoid macular edema [Efectividad de la indometacina tópica en la prevención del edema macular quístico del afaquico]. Archivos de la Sociedad Española de Oftalmología 1992;62(6):469‐76.
Sholiton 1979 {published data only}
    1. Sholiton DB, Reinhart WJ, Frank KE. Indomethacin as a means of preventing cystoid macular edema following intracapsular cataract extraction. Journal ‐ American Intra‐Ocular Implant Society 1979;5(2):137‐40. - PubMed
Tang 2015 {published data only}
    1. Tang H‐Y, Lu M, Hong D‐M, Ming G‐Y, Zeng Z‐R, Ling H‐J. Effect and safety of intrachamberal triamcinolone acetonide injection during cataract surgery in diabetic patients. International Eye Science 2015;15(3):474‐7. [DOI: ]
Wolf 2007 {published data only}
    1. Wolf EJ, Braunstein A, Shih C, Braunstein RE. Incidence of visually significant pseudophakic macular edema after uneventful phacoemulsification in patients treated with nepafenac. Journal of Cataract and Refractive Surgery 2007;33(9):1546‐9. - PubMed
Yamaaki 1984 {published data only}
    1. Yamaaki H, Hendrikse F, Deutman AF. Iris angiography after cataract extraction and the effect of indomethacin eyedrops. Ophthalmologica 1984;188(2):82‐6. - PubMed
Yilmaz 2012 {published data only}
    1. Yilmaz T, Cordero‐Coma M, Gallagher MJ. Ketorolac therapy for the prevention of acute pseudophakic cystoid macular edema: a systematic review. Eye 2012;26(2):252‐8. [DOI: ] - PMC - PubMed

References to studies awaiting assessment

CTRI/2009/091/001078 {unpublished data only}
    1. CTRI/2009/091/001078. Randomised, triple blinded, placebo controlled, clinical trial to compare the effect of Ketorolac tromethamine 0.4% in prophylactically preventing cystoid macula edema following cataract surgery. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1207 (accessed 5 October 2016).

References to ongoing studies

NCT01694212 {published data only}
    1. NCT01694212. Effect of perioperative topical diclofenac on intraocular inflammation after cataract surgery and the incidence of postoperative macular edema in patients with diabetic retinopathy. clinicaltrials.gov/ct2/show/NCT01694212 (accessed 5 October 2016).
NCT01774474 {published data only}
    1. NCT01774474. PRevention of Macular EDema after cataract surgery (PREMED). clinicaltrials.gov/ct2/show/NCT01774474 (accessed 5 October 2016).
NCT02646072 {published data only}
    1. NCT02646072. The effect of preoperative topical ketorolac 0.45% on aqueous cytokine levels and macular thickness in diabetic and non diabetic patients undergoing cataract surgery. clinicaltrials.gov/ct2/show/NCT02646072 (accessed 5 October 2016).

Additional references

Ahmed 2013
    1. Ahmed I, Everett A. Cystoid macular edema. In: Yanoff M, Duker JS editor(s). Ophthalmology. 4th Edition. Mosby, 2013:Section 6, page 34.
Atkins 2004
    1. Atkins D, Best D, Briss PA, Eccles M, Falck‐Ytter Y, Flottorp S, et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454):1490. - PMC - PubMed
Ballonzoli 2010
    1. Ballonzoli L, Bourcier T. Ocular side effects of steroids and other immunosuppressive agents. Therapie 2010;65(2):115‐20. - PubMed
Blomquist 2002
    1. Blomquist PH, Rugwani RM. Visual outcomes after vitreous loss during cataract surgery performed by residents. Journal of Cataract and Refractive Surgery 2002;28(5):847‐52. - PubMed
Carnahan 2000
    1. Carnahan MC, Goldstein DA. Ocular complications of topical, peri‐ocular, and systemic corticosteroids. Current Opinion in Ophthalmology 2000;11(6):478‐83. - PubMed
Choi 2005
    1. Choi J, Buzney SM, Weiter JJ. Cystoid macular edema: current modes of therapy. International Ophthalmology Clinics 2005;45(4):143‐51. - PubMed
Covidence 2016 [Computer program]
    1. Veritas Health Innovation. Covidence systematic review software. Melbourne: Veritas Health Innovation, (accessed prior to 30 September 2016).
Eisenach 2010
    1. Eisenach JC, Curry R, Tong C, Houle TT, Yaksh TL. Effects of intrathecal ketorolac on human experimental pain. Anesthesiology 2010;112(5):1216‐24. - PMC - PubMed
Flach 1987
    1. Flach AJ, Dolan BJ, Irvine AR. Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. American Journal of Ophthalmology 1987;103(4):479‐86. - PubMed
Flach 1988
    1. Flach AJ, Kraff MC, Sanders DR, Tanenbaum L. The quantitative effect of 0.5% ketorolac tromethamine solution and 0.1% dexamethasone sodium phosphate solution on postsurgical blood‐aqueous barrier. Archives of Ophthalmology 1988;106(4):480‐3. - PubMed
Flach 1989
    1. Flach AJ, Jaffe NS, Akers WA. The effect of ketorolac tromethamine in reducing postoperative inflammation: double‐mask parallel comparison with dexamethasone. Annals of Ophthalmology 1989;21(11):407‐11. - PubMed
Glanville 2006
    1. Glanville JM, Lefebvre C, Miles JN, Camosso‐Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130‐6. - PMC - PubMed
Gonzales 2013
    1. Gonzales JA, Gritz DC, Channa R, Quinto GG, Kim A, Chuck RS. Non‐steroidal anti‐inflammatory drugs versus corticosteroids for controlling inflammation after uncomplicated cataract surgery. Cochrane Database of Systematic Reviews 2013, Issue 5. [DOI: 10.1002/14651858.CD010516] - DOI - PMC - PubMed
Hee 1995
    1. Hee MR, Puliafito CA, Wong D, Duker JS, Reichel E, Rutledge B, et al. Quantitative assessment of macular edema with optical coherence tomography. Acta Ophthalmologica 1995;113(8):1019‐29. - PubMed
Heier 1999
    1. Heier J, Cheetham JK, Degryse R, Dirks MS, Caldwell DR, Silverstone DE, et al. Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: a randomized, vehicle‐controlled clinical trial. American Journal of Ophthalmology 1999;127(3):253‐9. - PubMed
Higgins 2011
    1. Higgins JP, Altman DG, Sterne JAC, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Jain 2001
    1. Jain R, Stevens JD, Bunce CV, Garrett C, Hykin PG. Ischaemic heart disease may predispose to pseudophakic cystoid macular oedema. Eye 2001;15(Pt 1):34‐8. - PubMed
Jaycock 2009
    1. Jaycock P, Johnston RL, Taylor H, Adams M, Tole DM, Galloway P, et al. The national cataract dataset electronic multi‐centre audit of 55,567 operations: updating the benchmark standards of care in the UK and internationally. Eye 2009;23(1):38‐49. - PubMed
Kessel 2014
    1. Kessel L, Tendal B, Jorgensen KJ, Erngaard D, Flesner P, Andresen JL, et al. Post‐cataract prevention of inflammation and macular edema by steroid and nonsteroidal anti‐inflammatory eye drops: a systematic review. Ophthalmology 2014;121:1915‐24. - PubMed
Kim 2015
    1. Kim SJ, Schoenberger SD, Thorne JE, Ehlers JP, Yeh S, Bakri SJ. Topical nonsteroidal anti‐inflammatory drugs and cataract surgery: a report by the American Academy of Ophthalmology. Ophthalmology 2015;122:2159‐68. - PubMed
Kim 2016
    1. Kim SJ, Jampel H. Prevention of cystoid macular edema after cataract surgery in non‐diabetic and diabetic patients: A systematic review and meta‐analysis. American Journal of Ophthalmology 2016;161:221‐2. - PubMed
Kim 2016a
    1. Kim SJ, Patel SN, Sternberg P Jr. Routine use of nonsteroidal anti‐inflammatory drugs with corticosteroids in cataract surgery: Beneficial or redundant?. Ophthalmology 2016;123(3):444‐6. - PubMed
Kraff 1990
    1. Kraff MC, Sanders DR, McGuigan L, Raanan MG. Inhibition of blood‐aqueous humor barrier breakdown with diclofenac. A fluorophotometric study. Archives of Ophthalmology 1990;108(3):380‐3. - PubMed
Miyake 1977
    1. Miyake K. Prevention of cystoid macular edema after lens extraction by topical indomethacin (I). A preliminary report. Albrecht von Graefes Archiv fur Klinische und Experimentelle Ophthalmologie 1977;203:81‐8. - PubMed
Miyake 1984
    1. Miyake K. Indomethacin in the treatment of postoperative cystoid macular edema. Survey of Ophthalmology 1984;28(Suppl):554‐68. - PubMed
Nelson 2003
    1. Nelson MS, Martidis A. Managing cystoid macular edema after cataract surgery. Current Opinion in Ophthalmology 2003;14(1):39‐43. - PubMed
Pascolini 2012
    1. Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. British Journal of Ophthalmology 2012;96(5):614‐8. - PubMed
Polanski 1992
    1. Polansky JR. Side effects of topical therapy with anti‐inflammatory steroids. Current Opinion in Ophthalmology 1992;3(2):259‐72.
RevMan 2014 [Computer program]
    1. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Rossetti 1998
    1. Rossetti L, Chaudhuri J, Dickersin K. Medical prophylaxis and treatment of cystoid macular edema after cataract surgery. The results of a meta‐analysis. Ophthalmology 1998;105(3):397‐405. - PubMed
Sanders 1984
    1. Sanders DR, Kraff M. Steroidal and nonsteroidal anti‐inflammatory agents. Effect on postsurgical inflammation and blood‐aqueous humor barrier breakdown. Archives of Ophthalmology 1984;102(10):1453‐6. - PubMed
Sivaprasad 2004
    1. Sivaprasad S, Bunce C, Patel N. Non‐steroidal anti‐inflammatory agents for treating cystoid macular oedema following cataract surgery. Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI: 10.1002/14651858.CD004239.pub2] - DOI - PubMed
Solomon 2001
    1. Solomon KD, Cheetham JK, DeGryse R, Brint SF, Rosenthal A. Topical ketorolac tromethamine 0.5% ophthalmic solution in ocular inflammation after cataract surgery. Ophthalmology 2001;108(2):331‐7. - PubMed
Spaide 1993
    1. Spaide RF, Yannuzzi LA, Sisco LJ. Chronic cystoid macular edema and predictors of visual acuity. Ophthalmic Surgery 1993;24(4):262‐7. - PubMed
Ursell 1999
    1. Ursell PG, Spalton DJ, Whitcup SM, Nussenblatt RB. Cystoid macular edema after phacoemulsification: relationship to blood‐aqueous barrier damage and visual acuity. Journal of Cataract and Refractive Surgery 1999;25(11):1492‐7. - PubMed
Warren 2008
    1. Warren KA, Fox JE. Topical nepenafac as an alternate treatment for cystoid macular edema in steroid responsive patients. Retina 2008;28(10):1427‐34. - PubMed
Warren 2010
    1. Warren K, Bahrani H, Fox JE. NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema. Retina 2010;30(2):260‐6. - PubMed
Wielders 2015
    1. Wielders LH, Lambermont VA, Schouten JS, Biggelaar FJ, Worthy G, Simons RW, et al. Prevention of cystoid macular edema after cataract surgery in nondiabetic and diabetic patients: a systematic review and meta‐analysis. American Journal of Ophthalmology 2015;160:968‐81. - PubMed
Yannuzzi 1995
    1. Yannuzzi LA, Guyer DR, Green WR. The Retina Atlas. 1st Edition. Elsevier Health Sciences, 1995.

References to other published versions of this review

Abeysiri 2011
    1. Abeysiri P, Wormald R, Bunce C. Prophylactic non‐steroidal anti‐inflammatory agents for the prevention of cystoid macular oedema after cataract surgery. Cochrane Database of Systematic Reviews 2011, Issue 6. [DOI: 10.1002/14651858.CD006683.pub2] - DOI
Goh 2007
    1. Goh D, Lim N. Prophylactic non‐steroidal anti‐inflammatory agents for the prevention of cystoid macular oedema after cataract surgery. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD006683] - DOI

Publication types

MeSH terms

Substances

LinkOut - more resources